An article in STAT News (Nov. 22) suggests that the FDA’s drug approval process and reliance on the “gold standard”will undergo “a seismic shift” in the Donald Trump administration. “Public health advocates are bracing for a seismic shift: a surrender of the agency’s rules for off-label promotion of drugs; the importation of more drugs from other countries;…

Read More